AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D).
The investment represents a substantial capital infusion to the $3.5bn announced in November 2024.
Go deeper with GlobalData
The focus of this investment is a manufacturing facility dedicated to producing drug substances for AstraZeneca’s weight management and metabolic product range.
This portfolio includes oral glucagon-like peptide-1 (GLP-1), baxdrostat, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) and combination small molecule treatments.
The new facility will be designed to manufacture peptides, small molecules and oligonucleotides.
To be constructed in the Commonwealth of Virginia, the plant will be AstraZeneca’s single manufacturing venture globally.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe new facility will incorporate advanced technologies such as AI, automation and data analytics to enhance production capabilities.
This financial commitment will generate new direct and indirect jobs in the US.
AstraZeneca CEO Pascal Soriot stated: “Today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80bn in revenue by 2030.”
The investment also covers other projects: the expansion of AstraZeneca’s R&D facility in Gaithersburg, Maryland, and the establishment of an advanced R&D centre in Kendall Square, Cambridge, Massachusetts.
The company will also develop next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California, as well as expand its continuous manufacturing operations in Mount Vernon, Indiana.
The investment encompasses the expansion of speciality manufacturing in Coppell, Texas, the establishment of new sites to support clinical trials, and an increase in funding for research and development of new medicines.
In July 2025, Modella AI entered a multi-year partnership with AstraZeneca aimed at accelerating AI-driven clinical development in oncology.
